Effect of agalsidase alfa replacement therapy on fabry disease-related hypertrophic cardiomyopathy: A 12- to 36-month, retrospective, blinded echocardiographic pooled analysis Academic Article uri icon

Overview

MeSH Major

  • Fabry Disease
  • Hypertrophy, Left Ventricular
  • alpha-Galactosidase

abstract

  • Treatment with agalsidase alfa for 12 or 36 months was associated with reduced LVM in these patients with Fabry disease with baseline LVH, and it appeared to stabilize LVM in these patients without baseline LVH.

publication date

  • September 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.clinthera.2009.09.008

PubMed ID

  • 19843486

Additional Document Info

start page

  • 1966

end page

  • 76

volume

  • 31

number

  • 9